Dermatology
Comments
Cutaneous T Cell Lymphoma: Update of TreatmentZackheim H.S.Department of Dermatology, University of California, San Francisco, Calif., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: October 22, 1999
Issue release date: 1999
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Abstract
The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicated for widespread infiltrated plaque and tumor stage disease. Low-dose methotrexate is often useful for resistant patch/plaque MF and erythrodermic CTCL. Interferon α (IFN-α) is indicated for methotrexate failures and recurrent tumors following TSEB therapy. Photopheresis may be helpful for early-stage erythrodermic CTCL but is very costly. Retinoids may be of value for early and moderately advanced CTCL particularly in combination with other agents such as IFN-α and PUVA. Systemic disease usually requires combination chemotherapy such as that used for non-Hodgkin’s lymphoma; however, responses are usually short lived.
Related Articles:
References
- Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 1996;88:2385–2409.
- Koh HK, Foss FM (eds): Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9: 943–1143.
- Zackheim HS, Kashani-Sabet M, Amin S: Topical corticosteroids for mycosis fungoides. Arch Dermatol 1998;134:949–954.
-
Ramsay DL, Meller JA, Zackheim HS: Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1031– 1056.
- Zackheim HS, Epstein EH Jr, Crain WR: Topical carmustine (BCNU) for cutaneous T-cell lymphoma. J Am Acad Dermatol 1990;22: 802–810.
- Resnick KS, Vonderheid EC: Home UV phototherapy of early mycosis fungoides: Long-term follow-up observations in thirty-one patients. J Am Acad Dermatol 1993;29:73–77.
- Hermann JJ, Roenigk HH Jr, Hurria A, Kuzel TM, Samuelson EM, Rademaker AW, Rosen ST: Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up. J Am Acad Dermatol 1995;33:234–242.
-
Morison WL, Baughman RD, Day RM, Forbes D, Hoenigsmann H, Krueger GG, Lebwohl M, Lew R, Naldi L, Parrish JA, Piepkorn M, Stern RS, Weinstein GD, Whitmore SE: Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998;134:595– 598.
-
Fraser-Andrews E, Seed P, Whittaker S, Russell-Jones R: Extracorporeal photopheresis in Sézary syndrome: No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998;134:1001– 1005.
-
Hoppe RT: Total skin electron beam therapy in the management of mycosis fungoides; in Vaeth JM, Meyer JL (eds): The Role of High Energy Electrons in the Treatment of Cancer. Front Radiat Ther Oncol. Basel, Karger, 1991, vol 25, pp 80–89.
- Wilson LD, Quiros PA, Kolenik SA, Heald PW, Braverman IM, Edelson RL, Kacinski BM: Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;35:69–73.
- Zackheim HS, Kashani-Sabet M, Hwang ST: Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;34:626–631.
- Vonderheid EC, Sajjadian A, Kadin ME: Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996;34:470–481.
- Thomsen K, Hammar H, Molin L, Volden G: Retinoids plus PUVA (RePUVA) in mycosis fungoides, plaque stage. Acta Derm Venereol 1989;69:536–538.
- Dreno B, Claudy A, Meynadier J, Verret JL, Souteyrand P, Ortonne JP, Kalin B, Godefroy WY, Beerblock K, Thill L: The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon α2a and etretinate. Br J Dermatol 1991;125:456–459.
- Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL: Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 1993;51:63–72.
-
Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome Hematol Oncol Clin North Am 1995;9:1109–1116.
-
Zaknoen SL: Nucleoside analogs in the systemic treatment of mycosis fungoides/Sézary syndrome. J Geriatr Dermatol 1997;5:364–369.
-
Foss FM, Kuzel TM: Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1127– 1137.
- Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC: Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39:63–73.
- Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG: Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: A clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998;31:583–588.
- Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, Steinberg SM, Ghosh BC, Stocker JL, Bastian A, Phares JC, Sausville EA: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1994;12:2051–2059.
- Zackheim HS, Amin S, Kashani-Sabet M, McMillan A: Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J Am Acad Dermatol 1999;40: 418–425.
Article / Publication Details
Published online: October 22, 1999
Issue release date: 1999
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
